A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)

Trial Profile

A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs Tasadenoturev (Primary) ; Interferon gamma
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Acronyms TARGET-I
  • Sponsors DNAtrix
  • Most Recent Events

    • 30 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 15 Mar 2018.
    • 02 Nov 2017 Results of a pooled analysis assessing 5-year outcomes in large cohort of patients from TARGET I and TARGET II (n=947) presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 06 Jun 2017 Results (n=27) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top